What is Normunity?
Normunity is a biotechnology company dedicated to creating novel anti-cancer therapies. Its approach centers on addressing untapped biological mechanisms at the interface of the immune system and the tumor, aiming to target pathways that influence tumor growth and overcome immune evasion. The company is building a diverse pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. Its lead program, NRM823, is a T cell engager designed for tumor-specific targeting across multiple solid tumors, with a projected clinical entry in 2025. Normunity operates from its bases in Boston, MA, and New Haven, CT.
How much funding has Normunity raised?
Normunity has raised a total of $140M across 2 funding rounds:
Series A
$65M
Series B
$75M
Series A (2022): $65M with participation from Sanofi Ventures, Taiho Ventures, Osage University Partners, and investorCanaan Ventures
Series B (2025): $75M led by Sanofi Ventures, Enavate Sciences, Pfizer, Connecticut Innovations, Samsara BioCapital, Canaan Partners, YK, Osage Venture Partners, Taiho Ventures, and Regeneron Ventures
Key Investors in Normunity
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi, particularly in oncology, immunology, and rare diseases.
Enavate Sciences
Enavate Sciences is committed to investing in and supporting the strategic growth of innovative therapeutic and enabling technology companies that have the potential to transform patient care and improve quality of life, considering a broad range of therapeutic areas at both pre-clinical and clinical stages.
Pfizer
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas, focusing on oncology, internal medicine, inflammation and immunology, and vaccines.
What's next for Normunity?
The substantial enterprise-level capital infusion positions Normunity for significant growth and pipeline expansion. The recent major strategic investment, particularly from established players in the pharmaceutical and venture capital sectors, signals strong confidence in the company's scientific approach and therapeutic potential. This backing is crucial for advancing NRM823 into clinical trials and further developing its pipeline of novel biologics. The company's focus on targeting mechanisms that circumvent immune surveillance suggests a strategy aimed at addressing unmet needs in oncology, potentially leading to breakthrough treatments for various solid tumors.
See full Normunity company page
